Cost-Utility Analysis of Dapagliflozin as an Add-On to Standard Treatment for Patients with Type 2 Diabetes and High Risk of Cardiovascular Disease in Thailand.
Chaicharn DeerochanawongKriengsak VareesangthipDilok PiyayotaiDittaya ThongsukNuch PojchaijongdeeUnchalee PermsuwanPublished in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2021)
On the basis of the DECLARE study with low incidence of T2DM complications and 4.2 years of median follow-up duration, the add-on dapagliflozin results in an ICER of 18,988 USD/QALY, which exceeds the local threshold of 5310 USD/QALY. Dapagliflozin would show better value for money in the context of high prevalence of T2DM complications.